Search results for "Nausea"

showing 10 items of 138 documents

Escitalopram causes fewer seizures in human overdose than citalopram

2010

Seizures are a recognized complication of acute overdose with the racemic (1:1 ratio of R- and S-enantiomers) selective serotonin reuptake inhibitor antidepressant citalopram.We tested the hypothesis that escitalopram (the therapeutically active S-enantiomer of citalopram) causes fewer seizures in overdose than citalopram at comparable doses of the S-enantiomer.Multicenter retrospective review of cases with citalopram and escitalopram overdose reported to German, Austrian, and Swiss Poisons Centers between 1997 and 2006.316 citalopram and 63 escitalopram cases were analyzed. Somnolence, nausea, vomiting, tachycardia, QT prolongation, and tremor occurred with similar frequency in both groups…

AdultMalePoison Control CentersAdolescentNauseaSerotonin reuptake inhibitor610 Medicine & healthCitalopramCitalopramToxicologyDrug overdosebehavioral disciplines and activitiesQT intervalYoung AdultSeizuresGermanymental disordersmedicineHumansEscitalopramAgedRetrospective StudiesAged 80 and over3005 ToxicologyStereoisomerismGeneral MedicineMiddle Agedmedicine.disease10199 Clinic for Clinical Pharmacology and ToxicologyAustriaAnesthesiaVomitingAntidepressantFemaleDrug Overdosemedicine.symptomPsychologySelective Serotonin Reuptake InhibitorsSwitzerlandmedicine.drug
researchProduct

Time course of adverse events most commonly associated with topiramate for migraine prevention

2007

The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double-blind, placebo-controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in/=2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double-blind, placebo-controlled, and 26-week trials. The pooled population comprised all randomized patients who reported safety data during the double-blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4-week titration period and a 22-week maintenance period. Incidence, time to onset, and cumulative mean rate of …

AdultMaleTopiramateTime FactorsNauseaMigraine DisordersPopulationFructosePlaceboTimelaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialTopiramatelawmedicineHumansParesthesiaeducationFatigueeducation.field_of_studyDose-Response Relationship Drugbusiness.industryNauseaMiddle Agedmedicine.diseaseAnorexiaDiscontinuationWithholding TreatmentNeurologyTolerabilityMigraineAnesthesiaPatient ComplianceAnticonvulsantsFemaleNeurology (clinical)medicine.symptomCognition Disordersbusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion

2012

Background/Aim:Liraglutide, a glucagon-like peptide-1 analog, induces weight loss. We investigated whether liraglutide affects gastric accommodation and satiation by measuring the intragastric pressure (IGP) during nutrient-drink consumption and using the barostat technique.Methods:Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration. IGP was studied during intragastric nutrient-drink (1.5 kcal ml(-1)) infusion (60 ml min(-1)), while the HVs scored their satiation on a graded scale until maximal satiation. In a separate session, isobaric distentions were performed using the barostat with stepwise increments of 2 mm Hg starting from minimal di…

AdultMaleendocrine systemmedicine.medical_specialtyManometryEndocrinology Diabetes and MetabolismTreatment outcomeMedicine (miscellaneous)SatiationSettore BIO/09 - FisiologiaBody Mass IndexBeveragesEatingDouble-Blind MethodGlucagon-Like Peptide 1Internal medicinegastric accomodation GLP-1 satiationPressuremedicineHumansIngestionNutrition and DieteticsDose-Response Relationship DrugLiraglutidebusiness.industryStomachdigestive oral and skin physiologyNauseaLiraglutidePostprandial PeriodTreatment OutcomeEndocrinologyGastric EmptyingFemaleGastrointestinal Motilitybusinessmedicine.drugInternational Journal of Obesity
researchProduct

Juvenile migraine and allodynia: results of a retrospective study.

2015

Background There are only 2 small sample studies investigating allodynia in the pediatric population. The aim of this study was to evaluate the frequency of allodynia during cephalalgic attacks in a juvenile population with primary headaches and its association with other symptoms of migraine. Methods We reviewed all medical records of patients with primary headache consecutively seen during a 2-year period. Frequency of allodynia was evaluated, by means of a questionnaire, consisting of 6 questions (for example: Do you avoid touching your head when you have a migraine attack?). Results Two hundred thirty children suffering from primary headache were seen during the study period. Two hundre…

AdultMalemedicine.medical_specialtyAdolescentDatabases FactualNauseaMigraine DisordersPopulationMotor ActivitySensitivity and SpecificityYoung AdultchildrenphonophobiaInternal medicineSurveys and QuestionnairesmedicineHumansmigraineLongitudinal StudieseducationallodyniaRetrospective Studieseducation.field_of_studybusiness.industryprimary headacheReproducibility of ResultsRetrospective cohort studyNauseaOdds ratiomedicine.diseaseConfidence intervalPhonophobiaAllodyniaNeurologyMigraineHyperalgesiaAnesthesiaMultivariate AnalysisSettore MED/26 - NeurologiaFemaleNeurology (clinical)medicine.symptombusinessHeadache
researchProduct

Incidence of postoperative nausea and vomiting (PONV) after general pre-anaesthetic prophylaxis with antihistamines

2004

AdultMalemedicine.medical_specialtyAllergyNeurologyVomitingAnesthetics GeneralImmunologyPharmacology toxicologyConscious SedationInternal medicinemedicineHumansAgedPharmacologybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseRheumatologyAnesthesiaPostoperative Nausea and VomitingHistamine H1 AntagonistsFemalemedicine.symptombusinessPostoperative nausea and vomitingInflammation Research
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.

2003

Aim  The standard treatment for patients with clinically resectable rectal cancer is surgery. Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+). In recent years, encouraging results of pre-operative radiotherapy have been reported. This prospective randomized phase-III-trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant RCT to standard postoperative RCT. We report on the design of the study and first results with regard to toxicity of RCT and postoperative morbidity. Patients and methods  Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50.4…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticNauseaColorectal cancermedicine.medical_treatment030230 surgerylaw.invention03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRandomized controlled triallawGermanymedicineHumansAgedNeoplasm Stagingbusiness.industryRectal NeoplasmsStandard treatmentPatient SelectionGastroenterologyPostoperative complicationRadiotherapy DosageMiddle Agedmedicine.diseaseTotal mesorectal excisionSurvival AnalysisNeoadjuvant Therapy3. Good healthSurgeryClinical trialRadiation therapyTreatment OutcomeChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeFemaleRadiotherapy AdjuvantFluorouracilmedicine.symptombusinessColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience

2017

The occurrence of thiopurine-related adverse events (AEs) may complicate the management of patients with inflammatory bowel disease (IBD). We aimed to evaluate the tolerability of thiopurines in a current IBD setting.All consecutive patients who started a treatment with azathioprine (AZA) from January 2010 to March 2016 were entered in a prospectively maintained database, and the AEs which led to the permanent discontinuation of the drug were reported.Two hundred and fifty three patients were included. Median total follow-up was 32 months (range: 0.2-75 months). At the end of the study, AZA was discontinued in 160 patients (63.2%). The main reason leading to drug withdrawal was the occurren…

AdultMalemedicine.medical_specialtyNauseaAzathioprineKaplan-Meier EstimateInflammatory bowel disease03 medical and health sciencesDrug withdrawal0302 clinical medicineInternal medicineAzathioprinemedicineHumansCumulative incidenceProspective StudiesAdverse effectMercaptopurinebusiness.industryGastroenterologyNauseaMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurgeryDiscontinuationItalyTolerability030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologymedicine.symptombusinessImmunosuppressive Agentsmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

Cisplatin preparation error; patient management and morbidity

2009

Introduction. Antineoplastic drug therapy errors represent a high iatrogenic potential due to antineoplastic drugs narrow therapeutic ranges and the complexity of chemotherapy regimens that may increase the risk of morbidity and mortality for oncology patients.Setting. We report a 57-year-old man with head and neck cancer who mistakenly received 180 mg/ m2of cisplatin overdose despite the safety measures and validations carried out during preparation. The patient developed moderate nausea and vomiting, acute renal failure, hearing difficulty (tinnitus), and severe myelodepression.Patient management. Prophylactic and symptomatic treatments were applied in order to prevent and correct toxicit…

AdultMalemedicine.medical_specialtyNauseaDrug CompoundingAntineoplastic drugmedicine.medical_treatmentAntineoplastic AgentsDrug overdoseMedication errorTinnitusmedicineHumansPharmacology (medical)Intensive care medicineBone Marrow DiseasesCisplatinChemotherapyMedical Errorsbusiness.industryNauseaAcute Kidney Injurymedicine.diseasePatient managementSurgeryOncologyHead and Neck NeoplasmsAntineoplastic DrugsCisplatinDrug Overdosemedicine.symptombusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Mirtazapine compared with paroxetine in major depression.

2000

Background: The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine. Method: 275 outpatients with a diagnosis of major depressive episode (DSM-IV) and a score ≥ 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and Clinical Global Impressions scales (Severity and Improvement), and analyses were performed on the intent-to-treat sample (127 mirtazapine-treated patients and 123 paroxetine-treated patients). Results: Mean daily doses were 32.7 mg of mirta…

AdultMalemedicine.medical_specialtyNauseaMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatryMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedParoxetinePsychiatry and Mental healthParoxetineTreatment OutcomeTolerabilityAnxietyFemalemedicine.symptomPsychologymedicine.drugThe Journal of clinical psychiatry
researchProduct